Олигометастатическая болезнь и дистанционная стереотаксическая абляционная радиотерапии тела. Часть ІV. Колоректалный рак

Олигометастатическая болезнь и дистанционная стереотаксическая абляционная радиотерапии тела. Часть ІV. Колоректалный рак

Автор: Паньшин Г.А.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзор

Статья в выпуске: 1 т.24, 2024 года.

Бесплатный доступ

Колоректальный рак является третьим наиболее распространенным раком в мире и имеет высокий уровень метастазирования, что является основной причиной смертности от данного заболевания. Олигометастатическое заболевание подразумевает под собой клиническое состояние, недавно включенное в рекомендации Европейского общества медицинской онкологии (ESMO), для которого может быть полезен более агрессивный локорегиональный подход.В настоящее время методы лечения пациентов с олигометастатической колоректальной карциномой быстро развиваются. Хотя операция остается золотым стандартом с благоприятным прогнозом при операбельном метастатическом поражении, к сожалению, большинство (70-80%) пациентов являются неподходящими кандидатами для резекции в силу клинических (сопутствующие заболевания) и/или хирургических технических факторов, таких как размер метастатической опухоли, ее анатомическое расположение, мультифокальность и ряд других. В этом плане именно дистанционная стереотаксическая абляционная радиотерапия тела, которая достаточно хорошо переносится пациентами, вплоть до возможности ее проведения в амбулаторных условиях, продлевает выживаемость пациентов без прогрессирования опухоли, улучшает общую продолжительность их жизни и иногда способствует полному излечению у определенной категории больных. В связи с этим ESMO объявила о включении в алгоритм лечения олигометастатической болезни как хирургической резекции, так и локальных абляционных методов лечения. В данном обзоре, являющемся продолжением серии статей об олигометастатической болезни у онкологических больных, предпринята попытка ознакомить читателя с современной ролью дистанционной стереотаксической абляционной лучевой терапии у пациентов с колоректальным раком.

Еще

Олигометастическая болезнь, стереотаксичекая абляционная радиотерапия тела, колоректальный рак

Короткий адрес: https://sciup.org/149145022

IDR: 149145022

Список литературы Олигометастатическая болезнь и дистанционная стереотаксическая абляционная радиотерапии тела. Часть ІV. Колоректалный рак

  • Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235.
  • Gill S, Liu DM, Green HM, Sharma RA. Beyond the Knife: The Evolving Nonsurgical Management of Oligometastatic Colorectal Cancer. Am Soc Clin Oncol Educ Book. 2018 May 23;38:209-219. doi: 10.1200/EDBK_200941.
  • Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, Faivre J. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive. Br J Surg. 1995 Oct;82(10):1397-1400. doi: 10.1002/bjs.1800821034.
  • Saltz LB. Metastatic colorectal cancer: is there one standard approach? Oncology (Williston Park). 2005 Aug;19(9):1147-54; discussion 1154, 1157-8, 1160. PMID: 16255132.
  • Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995 Jan-Feb;19(1):59-71. doi: 10.1007/BF00316981.
  • Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996 Apr 1;77(7):1254-1262. PMID: 8608500.
  • Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-318; discussion 318-321. doi: 10.1097/00000658-199909000-00004.
  • Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005 May;241(5):715-722, discussion 722-4. doi: 10.1097/01.sla.0000160703.75808.7d.
  • Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002 Jun;235(6):759-766. doi: 10.1097/00000658-200206000-00002.
  • Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006 May;141(5):460-466; discussion 466-467. doi: 10.1001/archsurg.141.5.460.
  • Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005 Aug;16(8):1311-1319. doi: 10.1093/annonc/mdi246.
  • Quan D, Gallinger S, Nhan C, Auer RA, Biagi JJ, Fletcher GG, et al; Surgical Oncology Program at Cancer Care Ontario. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery. 2012 Jun;151(6):860-870. doi: 10.1016/j.surg.2011.12.018.
  • Reed GB Jr, Cox AJ Jr. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol. 1966 Apr;48(4):597-611. PMID: 5327788.
  • Russell AH, Clyde C, Wasserman TH, Turner SS, Rotman M. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):117-123. doi: 10.1016/0360-3016(93)90428-x.
  • Gonzalez M, Ris HB, Krueger T, Gervaz P. Colorectal cancer and thoracic surgeons: close encounters of the third kind. Expert Rev Anticancer Ther. 2012 Apr;12(4):495-503. doi: 10.1586/era.12.21.
  • Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2013 Feb;20(2):572-579. doi: 10.1245/s10434-012-2726-3.
  • De Giacomo T, Rendina EA, Venuta F, Ciccone AM, Coloni GF. Thoracoscopic resection of solitary lung metastases from colorectal cancer is a viable therapeutic option. Chest. 1999 May;115(5):1441-1443. doi: 10.1378/chest.115.5.1441.
  • Welter S, Jacobs J, Krbek T, Krebs B, Stamatis G. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg. 2007 Jul;84(1):203-210. doi: 10.1016/j.athoracsur.2007.03.028.
  • Welter S, Theegarten D, Trarbach T, Maletzki F, Stamatis G, Tötsch M. Safety distance in the resection of colorectal lung metastases: a prospective evaluation of satellite tumor cells with immunohistochemistry. J Thorac Cardiovasc Surg. 2011 May;141(5):1218-1222. doi: 10.1016/j.jtcvs.2010.08.089.
  • Shiono S, Ishii G, Nagai K, Yoshida J, Nishimura M, Murata Y, et al. Predictive factors for local recurrence of resected colorectal lung metastases. Ann Thorac Surg. 2005 Sep;80(3):1040-1045. doi: 10.1016/j.athoracsur.2004.12.033.
  • Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G, Flentje M. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):186-196. doi: 10.1016/j.ijrobp.2004.02.060.
  • Fritz P, Kraus HJ, Mühlnickel W, Hammer U, Dölken W, Engel-Riedel W, Chemaissani A, Stoelben E. Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol. 2006 Aug 20;1:30. doi: 10.1186/1748-717X-1-30.
  • Guckenberger M, Heilman K, Wulf J, Mueller G, Beckmann G, Flentje M. Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol. 2007 Dec;85(3):435-442. doi: 10.1016/j.radonc.2007.10.044. Epub 2007 Nov 28. Erratum in: Radiother Oncol. 2008 Feb;86(2):293.
  • Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):398-403. doi: 10.1016/j.ijrobp.2008.01.002.
  • Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009 Apr 1;27(10):1579-1584. doi: 10.1200/JCO.2008.19.6386.
  • Cao C, Wang D, Tian DH, Wilson-Smith A, Huang J, Rimner A. A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases. J Thorac Dis. 2019 Dec;11(12):5187-5198. doi: 10.21037/jtd.2019.12.12.
  • Kim MS, Yoo SY, Cho CK, Yoo HJ, Choi CW, Seo YS, et al. Stereotactic body radiation therapy using three fractions for isolated lung recurrence from colorectal cancer. Oncology. 2009;76(3):212-219. doi: 10.1159/000201932.
  • Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011 Nov;101(2):255-259. doi: 10.1016/j.radonc.2011.05.033.
  • Qiu H, Katz AW, Chowdhry AK, Usuki KY, Singh DP, Metcalfe S, et al. Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer: Prognostic Factors for Disease Control and Survival. Am J Clin Oncol. 2018 Jan;41(1):53-58. doi: 10.1097/COC.0000000000000220.
  • Filippi AR, Badellino S, Ceccarelli M, Guarneri A, Franco P, Monagheddu C, et al. Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study. Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):524-529. doi: 10.1016/j.ijrobp.2014.10.046.
  • Carvajal C, Navarro-Martin A, Cacicedo J, Ramos R, Guedea F. Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results. J BUON. 2015 Jan-Feb;20(1):158-165. PMID: 25778311.
  • Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up. Clin Colorectal Cancer. 2017 Mar;16(1):58-64. doi: 10.1016/j.clcc.2016.07.004.
  • Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012 Jan;75(1):77-81. doi: 10.1016/j.lungcan.2011.04.021.
  • Rosenberg SA, Henke LE, Shaverdian N, Mittauer K, Wojcieszynski AP, Hullett CR, et al. A Multi-Institutional Experience of MR-Guided Liver Stereotactic Body Radiation Therapy. Adv Radiat Oncol. 2018 Aug 23;4(1):142-149. doi: 10.1016/j.adro.2018.08.005.
  • Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, et al. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):900-907. doi: 10.1016/j.ijrobp.2016.12.022.
  • Morias S, Marcu LG, Short M, Giles E, Potter A, Shepherd J, et al. Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy. J Oncol. 2018 Oct 4;2018:6483626. doi: 10.1155/2018/6483626.
  • Thompson R, Cheung P, Chu W, Myrehaug S, Poon I, Sahgal A, et al. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter. Radiother Oncol. 2020 Jan;142:236-245. doi: 10.1016/j.radonc.2019.08.018.
  • Saxby H, Chandy E, Phillips I, Ezhil V. Stereotactic ablative body radiotherapy for the treatment of colorectal oligometastases. Int J Radiat Oncol Biol Phys 2019;105:E173-174. doi: 10.1016/j.ijrobp.2019.06.2161.
  • Jingu K, Matsushita H, Yamamoto T, Umezawa R, Ishikawa Y, Takahashi N, et al. Stereotactic Radiotherapy for Pulmonary Oligometastases From Colorectal Cancer: A Systematic Review and Meta-Analysis. Technol Cancer Res Treat. 2018 Jan 1;17:1533033818794936. doi: 10.1177/1533033818794936.
  • Kinj R, Bondiau PY, François E, Gérard JP, Naghavi AO, Leysalle A, et al. Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy. Clin Colorectal Cancer. 2017 Sep;16(3):e211-e220. doi: 10.1016/j.clcc.2016.08.003.
  • Binkley MS, Trakul N, Jacobs LR, von Eyben R, Le QT, Maxim PG, et al. Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1044-1052. doi: 10.1016/j.ijrobp.2015.04.004.
  • Kobiela J, Spychalski P, Marvaso G, Ciardo D, Dell'Acqua V, Kraja F, et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review. Crit Rev Oncol Hematol. 2018 Sep;129:91-101. doi: 10.1016/j.critrevonc.2018.06.005.
  • Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F, et al. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiother Oncol. 2019 Apr;133:220-226. doi: 10.1016/j.radonc.2018.10.024.
  • Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A; SBRT for CRC liver metastases. Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. Radiother Oncol. 2018 Dec;129(3):427-434. doi: 10.1016/j.radonc.2018.06.035.
  • Guler OC, Hurmuz P, Atalar B, Yukselen Guney Y, Saglam EK, Akyurek S, et al. The Treatment Outcomes of Oligometastatic Colorectal Cancer Patients Treated with Stereotactic Body Radiation Therapy: A Multi-Institutional Analysis TROD 02-008. Int J Radiat Oncol Biol Phys 2022; 114(3)S:E143. doi: 10.1016/j.ijrobp.2022.07.988.
  • Palma DA, Olson R, Harrow S, Correa RJM, Schneiders F, Haasbeek CJA, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer. 2019 Aug 19;19(1):816. doi: 10.1186/s12885-019-5977-6. PMID: 31426760; PMCID: PMC6699121.
  • Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys 2018;102:S3-S4. doi: 10.1016/j.ijrobp.2018.06.105.OI.
  • Auclin E, Zaanan A, Vernerey D, Douard R, Gallois C, Laurent-Puig P, et al. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol. 2017 May 1;28(5):958-968. doi: 10.1093/annonc/mdx030.
  • Stintzing S, Wirapati P, Lenz HJ, Neureiter D, Fischer von Weikersthal L, et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. Ann Oncol. 2019 Nov 1;30(11):1796-1803. doi: 10.1093/annonc/mdz387.
  • McNair AG, Whistance RN, Forsythe RO, Rees J, Jones JE, Pullyblank AM, et al; CONSENSUS-CRC (Core Outcomes and Information Sets in Surgical Studies - Colorectal Cancer) Working Group. Synthesis and summary of patient-reported outcome measures to inform the development of a core outcome set in colorectal cancer surgery. Colorectal Dis. 2015 Nov;17(11):O217-229. doi: 10.1111/codi.13021.
  • Randomised Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer. Clinical trial: ACTRN12621001198819. Доступно по адресу: https://trials.cancervic.org.au/details.aspx?ID=vctl_actrnactrn12621001198819. Дата обращения: 14.12.2023.
  • Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study. Clinical trial: NCT05673148. Доступно по адресу: https://clinicaltrials.gov/study/NCT05673148. Дата обращения: 14.12.2023.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp